GILDC Stock Price and Chart — BCBA:GILDC

Key facts today

Gilead Sciences posted Q3 revenues of $7.77 billion, up 3% year-on-year, beating forecasts. The stock jumped 5.3% to $124.78 after the earnings report.

Gilead Sciences has licensed Assembly Biosciences' helicase-primase inhibitor programs for recurrent genital herpes, agreeing to a $35 million payment.

Analyze the impact Analyze the impact

About Gilead Sciences, Inc.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Check out other big names from the same industry as GILDC.